Showing results (861-870 of 1,007) with videos related to

Sort By:
Pageof 101
Parkinsonism & Related Disorders|September 28, 2020
Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal studyKelly A Mills, Ruth B Schneider, Marie Saint-Hilaire, et al.
Ophthalmology. Glaucoma|April 25, 2025
Prevalence of Myocilin Mutations in a Cohort of Patients with Juvenile Open-Angle Glaucoma from sub-Saharan AfricaOlusola Olawoye, Brian P Young, Angela W Nyunt, et al.
The Lancet. Neurology|February 11, 2014
Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trialPhillip A Low, David Robertson, Sid Gilman, et al.
Journal of Medicinal Chemistry|November 7, 2012
Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disordersAnatoly A Mazurov, David C Kombo, Terry A Hauser, et al.
Plos Genetics|May 31, 2014
Discovery and functional annotation of SIX6 variants in primary open-angle glaucomaMegan Ulmer Carnes, Yangfan P Liu, R Rand Allingham, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 1, 2005
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled studyDaniel Truong, Drake D Duane, Joseph Jankovic, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 12, 2009
Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppressionR Trappe, C Hinrichs, U Appel, et al.
Clinical Neuropharmacology|October 27, 2009
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effectsKelly E Lyons, Joseph H Friedman, Neal Hermanowicz, et al.
Human Molecular Genetics|May 4, 2011
Deficiency of α-actinin-3 is associated with increased susceptibility to contraction-induced damage and skeletal muscle remodelingJane T Seto, Monkol Lek, Kate G R Quinlan, et al.
JAMA Neurology|August 14, 2023
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical TrialRobert A Hauser, Alberto J Espay, Aaron L Ellenbogen, et al.
Pageof 101